POC for Verve? Plus IRA & East-West deals: a BioCentury podcast
A first for in vivo base editing therapy is met with investor disappointment
By Jeff Cranmer, Executive Editor
November 14, 2023 1:28 AM UTC
Verve Therapeutics Inc. (NASDAQ:VERV) achieved the first proof of concept for an in vivo base editing therapy, but investor concerns weighed on the company’s stock, clouding the readout’s reception. On the latest BioCentury This Week podcast, BioCentury’s editors dissect the data for VERVE-101 in heterozygous familial hypercholesterolemia and discuss how the choice of initial target and indication for a new modality or technology can have a major impact on how POC data are perceived by investors.
The editors also assess the latest developments related to the Inflation Reduction Act, including a National Pharmaceutical Council study showing how the law could impede collection of evidence about new indications for drugs, and assess a selection of biopharma deals, including a pair of sizable cross-border deals for Korea biotechs, a partnership between Legend Biotech Corp. (NASDAQ:LEGN) and Novartis AG (SIX:NOVN; NYSE:NVS) and the IPO by Cargo Therapeutics Inc. (NASDAQ:CRGX).
